ISCO Files Q1 2025 10-Q: Focus on Biotech & Skincare
Ticker: ISCO · Form: 10-Q · Filed: May 14, 2025 · CIK: 1355790
| Field | Detail |
|---|---|
| Company | International Stem Cell Corp (ISCO) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotech, skincare, pharmaceuticals
TL;DR
ISCO's Q1 2025 10-Q is in. Focus on biotech & skincare markets.
AI Summary
International Stem Cell Corp. (ISCO) filed its 10-Q for the quarter ending March 31, 2025. The company, formerly known as BTHC III INC., is involved in the pharmaceutical preparations sector and is headquartered in San Diego, CA. The filing covers the period from January 1, 2025, to March 31, 2025, and includes information on various market segments such as Anti-Aging Skincare, Biomedical, and Computer Equipment & Software.
Why It Matters
This filing provides insight into International Stem Cell Corp.'s financial performance and operational focus for the first quarter of 2025, particularly in its biomedical and anti-aging skincare markets.
Risk Assessment
Risk Level: medium — As a company in the pharmaceutical and biotech sector, ISCO faces inherent risks related to research, development, regulatory approval, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-01-01 — Reporting Period Start Date (Indicates the start of the financial quarter being reported.)
- 2024-12-31 — Previous Year End Date (Provides a point of comparison for financial performance.)
Key Players & Entities
- International Stem Cell CORP (company) — Filer of the 10-Q
- BTHC III INC. (company) — Former name of International Stem Cell Corp.
- 20250331 (date) — End of the reporting period
- 20250514 (date) — Filing date
- San Diego, CA (location) — Company headquarters
FAQ
What specific financial results are reported for the quarter ending March 31, 2025?
The provided text is a header and does not contain specific financial results for the quarter ending March 31, 2025. A full review of the 10-Q document is required for this information.
What are the primary market segments International Stem Cell Corp. operates in?
The filing indicates operations in 'AntiAgingSkincareMarket', 'BiomedicalMarket', and 'ComputerEquipmentAndSoftware'.
When was International Stem Cell Corp. formerly known as?
The company was formerly known as BTHC III INC., with a name change date of March 10, 2006.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What type of stock is mentioned in relation to the reporting period?
The filing mentions 'us-gaap:SeriesBPreferredStockMember' as of March 31, 2025, and 'us-gaap:RestrictedStockUnitsRSUMember' for the period January 1, 2025, to March 31, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding International Stem Cell CORP (ISCO).